LOS ANGELES, Calif., July 14, 2026
Spinogenix, Inc. has announced encouraging long-term clinical data demonstrating that its investigational therapy Tazbentetol (SPG302) delivered durable cognitive improvements for up to 84 weeks in patients with Alzheimer’s disease (AD) who continued treatment under a Special Access Scheme (SAS) following completion of the company’s Phase 2a clinical trial. The findings, presented at the Alzheimer’s Association International Conference (AAIC) 2026, reinforce the potential of Tazbentetol, a first-in-class oral synaptic regenerative therapy, to provide sustained cognitive benefits while maintaining a favorable safety and tolerability profile. The extended observations build upon previously reported placebo-controlled Phase 2a results and highlight the therapy’s potential to restore synaptic function rather than simply slowing disease progression. As Alzheimer’s disease continues to affect millions of people worldwide, these long-term data support the advancement of a novel therapeutic strategy aimed at improving cognition through synaptic regeneration, offering renewed optimism for patients, caregivers, and clinicians seeking more effective disease-modifying treatments.
Extended Treatment Demonstrates Durable Cognitive Improvement
The new data come from patients who elected to continue receiving 300 mg once-daily Tazbentetol through Australia’s Special Access Scheme after completing the company’s Phase 2a clinical study involving 24 patients with mild-to-moderate Alzheimer’s disease. The original study included a four-week randomized, double-blind, placebo-controlled period, followed by a 24-week open-label extension, during which all participants received active treatment. Earlier findings presented at CTAD 2025 demonstrated rapid cognitive improvement, with patients achieving an average increase of more than two points on the Standardized Mini-Mental Status Examination (SMMSE) while also showing meaningful reductions in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scores, an FDA-recognized efficacy endpoint. The newly reported extension data reveal that these cognitive improvements remained sustained for as long as 84 weeks, supporting the possibility that continued treatment may provide durable clinical benefits well beyond one year while maintaining a favorable safety profile both as monotherapy and alongside standard Alzheimer’s medications.
Case Study Highlights Real-World Functional Benefits
Among the most notable presentations at AAIC 2026 was a detailed case study describing a 72-year-old woman with mild Alzheimer’s disease who experienced remarkable functional improvements following treatment with Tazbentetol. Within three months of initiating therapy, her caregiver reported that she regained the ability to read books, follow movie storylines, and recall previously forgotten information, reflecting meaningful improvements in daily cognitive functioning. These observations were supported by objective clinical measures, including a 4- to 6-point increase in SMMSE scores and a 2.5-point reduction in CDR-SB scores, with additional improvement observed throughout the 24-week treatment period and sustained cognitive gains extending to 81 weeks. The close agreement between caregiver-reported improvements and validated clinical outcome measures strengthens confidence in the therapy’s potential to deliver meaningful real-world benefits for individuals living with Alzheimer’s disease.
Advertisement
Spinogenix Advances First-in-Class Synaptic Regenerative Therapy
Unlike many currently approved Alzheimer’s therapies that primarily aim to slow disease progression, Tazbentetol has been designed to restore depleted synapses and regenerate neuronal connections, addressing one of the fundamental biological drivers of cognitive decline. Spinogenix believes this synaptic regenerative approach may offer a transformative strategy for treating neurodegenerative disorders, with ongoing development also targeting amyotrophic lateral sclerosis (ALS), schizophrenia, and other neurological diseases. Company leadership emphasized that the encouraging long-term efficacy and safety findings provide strong support for planning the next stage of Alzheimer’s clinical development. As interest continues to grow in therapies capable of restoring brain function rather than merely delaying deterioration, the latest 84-week clinical data position Spinogenix as an emerging innovator in neurodegenerative disease research and strengthen the scientific rationale for advancing Tazbentetol into larger, later-stage clinical trials.
Source: Spinogenix press release
